Decision Resources, Inc., one of the world's leading research and advisory firms focusing on healthcare insights and analysis, announced today that it acquired BioTrends Research Group, the leader in providing specialized, syndicated market research in clinically complex, small to mid-size pharmaceutical markets. The acquisition of Exton, Penn.-based BioTrends by Waltham, Mass.-based Decision Resources, Inc. will result in a significant expansion of Decision Resources, Inc.'s Portfolio Planning segment of the Biopharma business unit.

Jason LaBonte, Ph.D., newly appointed Chief Operating Officer, Biopharma Portfolio Planning and Optimization said, "This important acquisition expands the breadth of our disease coverage. BioTrends' deep clinical intimacy with specialized pharmaceutical markets and primary research-focused model enhances our high-value offerings to the biopharma industry."

BioTrends is particularly well-known in the nephrology market, offering unique insights on drugs in that market. They also cover dermatology, gastroenterology, immunology/infectious disease and rheumatology markets and, as the newest company in the Decision Resources, Inc. portfolio, plan to expand their coverage of diseases.

"We are excited to begin our next wave of growth as a Decision Resources, Inc. company," said Jennifer Robinson, president of BioTrends. "We bring to the table an emphasis on quality and a level of detail in our syndicated research that is second-to-none."

  BioTrends will remain headquartered in Exton, Penn.    About BioTrends Research Group, Inc.  

BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For more information, please visit

About Decision Resources, Inc.

Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources, Inc. consists of two business units. The Medical Technology business unit includes Millennium Research Group, the global authority on medical device market intelligence. The Biopharma business unit consists of five companies: Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries; Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues; Fingertip Formulary, the leading provider of access to and insight into formulary data in the United States; HealthLeaders-InterStudy, the leading provider of managed care market intelligence; and Manhattan Research, the leading provider of access to physician and consumer opinions on the global healthcare market. For more information, please visit

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Chris Comfort   Decision Resources, Inc.   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Chris Comfort of Decision Resources, Inc., +1-781-296-2597,

Jazz Pharmaceuticals/UCB's Sodium Oxybate Will Account for More Than 15 Percent of the Fibromyalgia Drug Market in 2018

View Now